BCAL Diagnostics (ASX: BDX) has expanded access to its early cancer detection tests by embedding referral pathways into major clinical software systems used by general practitioners and specialists.
Clinical referral forms for the blood tests are now live on the Best Practice, Medical Director, and Genie (Magentus) management platforms used by approximately 97% of Australian general and specialist medical practices.
The move provides BCAL with a national access pathway into primary care, where patient risk assessment and referral decisions are commonly made.
It also complements the company’s existing laboratory and distribution arrangements with Sonic Healthcare and Healius Pathology to support national test access and fulfilment.
New Telehealth Service
BCAL has launched telehealth service EarlyDetection.com.au, developed with Medmate to provide an additional medically-supported pathway for eligible patients to access its early cancer detection tests.
The company has appointed Dr Martin A Devitt to lead the service, strengthening clinical governance as BCAL expands access to its testing portfolio.
The EarlyDetection platform is registered in New Zealand, the UK, the US, India and other countries in support of BCAL’s longer-term strategy of developing scalable global access pathways for its early detection portfolio that includes BREASTESTplus, and the cutting-edge, DNA-based Avantect blood tests for pancreatic and ovarian cancer.
A new Avantect multi-cancer early detection test is scheduled for lauch to the Australian market next month.
Key Commercialisation Milestone
BCAL executive chair Jayne Shaw said the scaled distribution of early detection tests through existing healthcare workflows was an important commercialisation milestone.
“Our GP, specialist, telehealth, and clinic channels are designed to make it easier for clinicians and patients to access our test portfolio, supporting broader national adoption of blood-based early cancer detection,” she said.
“This infrastructure is particularly important as we expand access to tests addressing significant market opportunities including pancreatic cancer, where we have previously estimated the Australian addressable market alone to be greater than $250 million per annum.”
Ms Shaw said BCAL had recently established a high-risk early detection clinic in Sydney to support patients who may benefit from medical consultation, risk assessment, and access to blood-based testing.
